$86.46+1.42 (+1.67%)
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally.
Nektar Therapeutics in the Healthcare sector is trading at $86.46. The stock is currently 21% below its 52-week high of $109.00, remaining 60.8% above its 200-day moving average. Technical signals show neutral RSI of 57 and bearish MACD signal, explaining why NKTR maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune s...
Nektar Therapeutics (NASDAQ:NKTR) presented 52-week top-line results from a 16-week blinded treatment extension of its Phase 2b REZOLVE-AA study evaluating rezpegaldesleukin (rezpeg) in adults with severe to very severe alopecia areata, emphasizing that additional dosing beyond 36 weeks increased th
Nektar (NKTR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
The biotech reported solid results from its investigational immunology drug in the treatment of a hair-loss disorder.
Shares of Nektar Therapeutics surged Monday after the company reported promising results for its experimental alopecia treatment.
Health care stocks declined late Monday afternoon, with the NYSE Health Care Index down 1.1% and the